Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000700810 | SCV000829582 | likely pathogenic | Severe X-linked myotubular myopathy | 2022-08-23 | criteria provided, single submitter | clinical testing | This missense change has been observed in individuals with X-linked myotubular myopathy (XLMTM) (PMID: 10063835, 11793470, 12031625). ClinVar contains an entry for this variant (Variation ID: 577943). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MTM1 protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant disrupts the p.Gly402 amino acid residue in MTM1. Other variant(s) that disrupt this residue have been observed in individuals with MTM1-related conditions (PMID: 9305655, 9829274), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 402 of the MTM1 protein (p.Gly402Arg). This variant is not present in population databases (gnomAD no frequency). |